Pharmaceutical Research

, Volume 17, Issue 12, pp 1494–1502 | Cite as

Safety, Toxicokinetics and Tissue Distribution of Long-Term Intravenous Liposomal Amphotericin B (ambisome®): A 91-day Study in Rats

  • Ihor Bekersky
  • Garry W. Boswell
  • Richard Hiles
  • Robert M. Fielding
  • Donald Buell
  • Thomas J. Walsh


Purpose. Amphotericin B in small, unilamellar liposomes (AmBisome) is safer and produces higher plasma concentrations than other formulations. Because liposomes may increase and prolong tissue exposures, the potential for drug accumulation or delayed toxicity after chronic AmBisome was investigated.

Methods. Rats (174/sex) received intravenous AmBisome (1, 4, or 12 mg/kg), dextrose, or empty liposomes for 91 days with a 30-day recovery. Safety (including clinical and microscopic pathology) and toxicokinetics in plasma and tissues were evaluated.

Results. Chemical and histopathologic changes demonstrated that the kidneys and liver were the target organs for chronic AmBisome toxicity. Nephrotoxicity was moderate (urean nitrogen [BUN] ≤51 mg/dl; creatinine unchanged). Liposome-related changes (vacuolated macrophages and hypercholesterolemia) were also observed. Although plasma and tissue accumulation was nonlinear and progressive (clearance and volume decreased, half-life increased with dose and time), most toxic changes occurred early, stabilized by the end of dosing, and reversed during recovery. There were no delayed toxicities. Concentrations in liver and spleen greatly exceeded those in plasma; kidney and lung concentrations were similar to those in plasma. Elimination half-lives were 1-4 weeks in all tissues.

Conclusions. Despite nonlinear accumulation, AmBisome revealed predictable hepatic and renal toxicities after 91 days, with no new or delayed effects after prolonged treatment at high doses that resulted in plasma levels >200 μg/ml and tissue levels >3000 μg/g.

amphotericin B liposomes pharmacokinetics toxicokinetics tissue distribution toxicity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    I. Bekersky, R. M. Fielding, D. Buell, and I. Lawrence. Lipidbased amphotericin B formulations: from animals to man. Pharm. Sci. Technol. Today 2:230–236 (1999).Google Scholar
  2. 2.
    R. M. Fielding, A. W. Singer, L. H. Wang, S. Babbar, and L. S. S. Guo. Relationship of pharmacokinetics and tissue distribution to reduced toxicity of colloidal amphotericin B in dogs. Antimicrob. Agents Chemother. 36:299–307 (1992).Google Scholar
  3. 3.
    K. M. Wasan, A. L. Kennedy, S. M. Cassidy, et al. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. 42:3146–3152 (1998).Google Scholar
  4. 4.
    J. P. Sculier, A. Coune, F. Meunier. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur. J. Cancer Clin. Oncol. 24:527–538 (1988).Google Scholar
  5. 5.
    G. Lopez-Berestein, V. Fainstein, R. Hopfer, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study. J. Infect. Dis. 151:704–710 (1985).Google Scholar
  6. 6.
    R. P. Rapp, P. O. Gubbins, and M. E. Evans. Amphotericin B lipid complex. Ann. Pharmacother. 31:1174–86 (1997).Google Scholar
  7. 7.
    R. T. Proffitt, A. Satorius, S.-M. Chiang. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28(suppl. B):49–61 (1991).Google Scholar
  8. 8.
    K. V. Clemons and D. A. Stevens. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J. Antimicrob. Chemother. 32:465–472 (1993).Google Scholar
  9. 9.
    T. J. Walsh, V. Yeldandi, M. McEvoy. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 42:2391–2398 (1998).Google Scholar
  10. 10.
    T. J. Walsh, R. W. Finberg, C. Arndt. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New Engl. J. Med. 340:764 (1999).Google Scholar
  11. 11.
    J. R. Wingard, M. H. White, E. J. Anaissie. A randomized double-blind safety study of AmBisome and Abelcet in febrile neutropenic patients. 9th Focus on Fungal Infections Meeting, March 1999, San Diego, CA, Abstr. 15.Google Scholar
  12. 12.
    I. Bekersky, D. Buell, M. Tomishima, K. Maki, I. Lawrence, and R. M. Fielding. New approaches to systemic antifungal therapy: Case studies of AmBisome and FK463. Recent Res. Devel. Antimicrob. Agents Chemother. 3:407–413 (1999).Google Scholar
  13. 13.
    A. J. Coukell and R. N. Brogden. Liposomal amphotericin B: Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55:585–612 (1998).Google Scholar
  14. 14.
    G. W. Boswell, D. Buell, and I. Bekersky. AmBisome (liposomal amphotericin B): a comparative review. J. Clin. Pharmacol. 38: 583–592 (1998).Google Scholar
  15. 15.
    T. J. Walsh, E. J. Anaissie, J. L. Goodman. High-dose liposomal amphotericin B in patients infected with aspergillosis and other filamentous fungi. In Abstracts 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society of Microbiology, Washington, DC, 1999, p. 573.Google Scholar
  16. 16.
    G. W. Boswell, I. Bekersky, D. Buell, R. Hiles, and T. J. Walsh. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob. Agents Chemother. 42:263–268 (1998).Google Scholar
  17. 17.
    I. Bekersky, G. W. Boswell, R. Hiles, R. M. Fielding, D. Buell, and T. J. Walsh. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in Beagle dogs. Pharm. Res. 16:1694–1701(1999).Google Scholar
  18. 18.
    R. M. Fielding, R. O. Lewis, and L. Moon-McDermott. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome®). Pharm. Res., 15:1775–1781 (1998).Google Scholar
  19. 19.
    A. Alak, S. Moys, and I. Bekersky. A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Ther. Drug Monit. 18: 604–609 (1996).Google Scholar
  20. 20.
    A. C. Parekh, R. J. Creno, and C. V. Dave. Hypercholesterolemic effect of amphotericin B: an analytical approach. Res. Commun. Chem. Pathol. Pharmacol. 9:307–314 (1974).Google Scholar
  21. 21.
    A. D. Dayan and P. K. Working. Non-clinical studies of the efficacy, pharmacokinetics and safety of amphotericin B colloidal dispersion (ABCD). Round Table Ser. R. Soc. Med. Press 32:12–26 (1994).Google Scholar
  22. 22.
    P. Longuet, V. Joly, P. Amirault, N. Seta, C. Carbon, and P. Yeni. Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats. Antimicrob. Agents Chemother. 35:1303–1308 (1991).Google Scholar
  23. 23.
    P. K. Working, M. S. Newman, T. Sullivan, M. Brunner, M. Podell, Z. Sahenk, and N. Turner. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in longcirculating, pegylated liposomes in cynomolgus monkeys. Toxicol. Sci. 46:155–165 (1998).Google Scholar
  24. 24.
    R. M. Fielding, G. Mukwaya, and R. A. Sandhaus. Clinical and preclinical studies with low-clearance liposomal Amikacin (Mi-Kasome). In M. C. Woodle and G. Storm (eds.), Long-Circulating Liposomes: Old Drugs, New Therapeutics, Springer-Verlag, Berlin, 1998, pp. 213–225.Google Scholar
  25. 25.
    J. P. Tolins and L. Raij. Chronic amphotericin B nephrotoxocity in the rat: Protective effect of calcium channel blockade. J. Am. Soc. Nephrol. 2:98–102 (1991).Google Scholar
  26. 26.
    L. H. Wang, R. M. Fielding, P. C. Smith, and L. S. S. Guo. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats. Pharm. Res. 12:275–283 (1995).Google Scholar
  27. 27.
    H.-H. Chow, Y. Cai, and M. Mayersohn. Disposition kinetics of amphotericin B in rats, the influence of dose. Drug Metab. Disp. 20:432–435 (1992).Google Scholar
  28. 28.
    R. M. Fielding, P. C. Smith, L. H. Wang, J. Porter, and L. S. S. Guo. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob. Agents Chemother. 35:1208–1213 (1991).Google Scholar
  29. 29.
    H. Ellens, E. Mayhew, and Y. M. Rustum. Reversible depression of the reticuloendothelial system by liposomes. Biochim. Biophys. Acta 714:479–485 (1982).Google Scholar
  30. 30.
    H. Harashima and H. Kiwada. Liposomal targeting and drug delivery: kinetic consideration. Adv. Drug Deliv. Rev. 19:425–444 (1996).Google Scholar

Copyright information

© Plenum Publishing Corporation 2000

Authors and Affiliations

  • Ihor Bekersky
    • 1
  • Garry W. Boswell
    • 2
  • Richard Hiles
    • 3
  • Robert M. Fielding
    • 4
  • Donald Buell
    • 5
  • Thomas J. Walsh
    • 6
  1. 1.Fujisawa Healthcare Inc.Deerfield
  2. 2.Calvert Preclinical ServicesOlyphant
  3. 3.Amylin Pharmaceuticals, Inc.San Diego
  4. 4.Biologistic ServicesBoulder
  5. 5.Fujisawa Healthcare Inc.Deerfield
  6. 6.lmmunocompromised Host Section, Pediatric Oncology BranchNational Cancer InstituteBethesda

Personalised recommendations